Author/Authors :
Sadeghizadehc, Majid Department of Molecular Genetics - Faculty of Biological Sciences - Tarbiat Modares University - Tehran, Iran , Djalali ,Mona Department of Molecular Genetics - Faculty of Biological Sciences - Tarbiat Modares University - Tehran, Iran , Djalali , Mahmoud Department of Cellular and Molecular Nutrition - School of Nutritional Sciences and Dietetics - Tehran University of Medical Sciences - Tehran, Iran , Abdolahi , Mina Department of Cellular and Molecular Nutrition - School of Nutritional Sciences and Dietetics - Tehran University of Medical Sciences - Tehran, Iran , Mohammadi , Hamed Student Research Committee - Department of Clinical Nutrition, School of Nutrition and Food Science - Isfahan University of Medical Sciences - Isfahan, Iran , Heidari , Hajar Student Research Committee - Department of Clinical Nutrition, School of Nutrition and Food Science - Isfahan University of Medical Sciences - Isfahan, Iran , Hosseini , Shayesteh Faculty of Basic Sciences - Tehran Branch - Islamic Azad University - Tehran, Iran
Abstract :
This study was designed to investigate the effect of nano-curcumin supplementation on pentraxin
3 (PTX3) gene expression and serum level in migraine patients.
Methods: The present study, performed as a clinical trial, included 38 episodic migraine patients in two
groups that received either nano-curcumin or placebo over a two-month period. At the start and the end of
the study, PTX3 gene expression and serum levels were measured.
Results: After two months of treatment, PTX3 gene expression and serum levels were both significantly less in
the nano-curcumin than in the placebo group (P= 0.01 and P< 0.001, respectively). No significant gene expression
differences were found between the two groups.
Conclusions: Curcumin may have a potential inhibitory effect on PTX3 gene expression and serum levels in
migraine disease and can be considered as an efficient therapy in migraine management.
Keywords :
Pentraxin 3 , Migraine , Curcumin - Inflammation , Clinical trial
